NEW YORK (
was downgraded to at Deutsche Bank to hold and given a new price target of $98. Allergan's risk profile and future earnings estimates suffered as the FDA announced a nonclinical study pathway for generics to produce Restasis, AGN's second largest drug, Deutsche said.
Allergan was downgraded at Leerink Swann. Future earnings estimates have been lowered as concern mounts over generic production of the firm's second largest drug, said Leerink Swann. New market perform rating, price target $102.
was upgraded at FBR Capital Markets to outperform from market perform. $5.50 price target. Business appears to have stabilized for now, FBR Capital Markets said.
was upgraded to buy at Goldman Sachs. $47 price target. Company is leveraged to an increase in volatility, Goldman said.
was upgraded at Goldman Sachs to neutral from sell. Valuation call, based on a $70 price target, Goldman said.
was downgraded at Goldman Sachs to neutral from buy. Estimates were also cut, as the company is buying back fewer shares, Goldman Sachs said.
was downgraded at J.P.Morgan to underweight from neutral. U.S. crop fundamentals have passed their peak, J.P. Morgan said.
Digital Realty Trust
was upgraded at UBS to neutral from sell. The risk/reward is balanced at current levels, UBS said.
was upgraded at Citigroup to neutral from sell. There's an expectation for a pickup in U.S.-centric flows, said Citigroup.
was initiated with an overweight rating at J.P. Morgan. $64 price target. Company should benefit from industry consolidation, J.P. Morgan said.
was upgraded at Goldman Sachs to neutral from sell. $68 price target. Company has solid margins and can exceed earnings expectations, Goldman Sachs said.
was downgraded to hold at TheStreet Ratings.
was downgraded at Wells Fargo to underperform from market perform. Company is losing its pricing power, Wells Fargo said.
was downgraded at Goldman Sachs. Valuation call, based on a $69 price target, Goldman said.
was downgraded at Wells Fargo to market perform from outperform. Industry competition is rising, Wells Fargo said.
was upgraded at Compass Point to buy from neutral. $26 price target. Company could boost earnings by paying debt early and may be a takeover candidate, Compass Point said.
was upgraded at Goldman Sachs to buy from neutral. Company has an attractive valuation and can deliver strong earnings growth, Goldman Sachs said.
was upgraded at Piper Jaffray to overweight from neutral. $121 price target. Visibility catalysts are improving, Piper Jaffray said.
was downgraded at Citigroup to neutral. Slower growth in China and Brazil and slowing backlog, said Citigroup.
was downgraded at Pacific Crest to underperform. Limited growth prospects and lower earnings projections, Pacific Crest said. Recent settlements and negative rulings suggest weakening patent value, Pacific Crest also said.
Also see: Trends Car Shoppers Should Know in 2013>>
was upgraded at Citigroup to buy from sell, as rate expectations shift and earnings normalize, said Citigroup. Price target goes to $24.
was initiated with a buy rating at UBS. $215 price target. Best-in-class play on pro paint volume increases, UBS said.
T. Rowe Price
was upgraded at Citigroup to buy as U.S. retail cash flows back into domestic equities, said Citigroup. Price target goes to $82.
was downgraded at Citigroup to neutral. Reflects the impact of declines in mining capex on the company, said Citigroup. Price target goes to $73.
was downgraded to sell at TheStreet Ratings.
was downgraded at Cantor Fitzgerald to hold from buy. Valuation call, based on a $49 price target, Cantor said.
was upgraded at Cowen to outperform from market perform. $112 price target Estimates were also boosted, given higher expected ethylene margins, Cowen said.
STOCK COMMENTS/EPS CHANGES
estimates, price target were reduced at Jefferies. Shares are now seen reaching $405. Estimates were also cut, given lower expected iPhone sales, Jefferies said. Hold rating.
price target and estimates were raised at BMO Capital Markets. Shares are now seen reaching $450. Estimates were also increased due to the companies near-term gross margin growth, BMO Capital Markets said.
Bed Bath & Beyond
numbers were raised at UBS. Earnings estimates were increased given increased visibility to a recovery in home furnishings demand, said UBS. Price target goes to $74.
numbers were cut at UBS. Earnings estimates were reduced given sell-through concerns, said UBS. Price target is $13.
estimates, price target were increased at Bank of America/Merrill Lynch. Estimates were boosted through 2015. Just conducted a bullish dealer survey, BofA/Merrill said. Buy rating and new $50 price target.
estimates, price target were increased at J.P. Morgan through 2014. Search pricing potential is increasing, J.P. Morgan said. Overweight rating and new $1,025 price target.
price target was raised at Citigroup to $96. The Ventures equity stake was marked to market, said Citigroup. Estimates were also adjusted.
price target and estimates were reduced at BMO Capital Markets. Estimates were reduced on increased competition in the SGLT2 drug market, said BMO Capital Markets. Price target was decreased to $52.
estimates, price target were cut at Bank of America/Merrill Lynch. Shares are now seen reaching $160. Estimates were also reduced, given currency headwinds and the disruption in Brazil. Buy rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.